News Sentiment

RGNX sentiment intelligence

Regenxbio Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 45 Balanced news tone 62 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 9.89 Week of 17 Jul 2026
Weighted tone 45/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

79/100 classification confidence.

Company focus 53

directly relevant articles

Source quality 1

high-authority source matches

Trend context Trend inactive

-29.1% over one week, +26.8% over four weeks, trend inactive, and near fair-value range.

Latest direct headline Negative

Lawsuit alleges Regenxbio misled investors on gene therapy trial results for Hurler Syndrome.

Market Reaction

Price moving ahead of tone

64/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 79/100 classification
One-week reaction -29.1% Price reacting lower
Trend fit Trend inactive 26.8% over four weeks
Fair value -17.8% Near fair-value range

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 9
Neutral 34
Negative 19

Relevance

Why the article matched

Direct first
Direct company coverage 53
Industry context 9
Sector context 0

Sources

Coverage mix

Publishers
Stock Titan 11
Market source 8
Investing.com 5
MT Newswires 4
simplywall.st 4
PR Newswire 3
GuruFocus 3
AllSci 2

Event Lens

What the news is about

Classified themes
Market update 33
Earnings 10
Regulatory and legal 8
Balance sheet 5
Guidance 2
Deals and strategy 2
Analyst action 2

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 62
Pluang Direct company coverage

Lawsuit alleges Regenxbio misled investors on gene therapy trial results for Hurler Syndrome.

Kuehn Law is investigating Regenxbio, Inc. over allegations of providing false or misleading information regarding the safety and efficacy of its gene therapy trial for Hurler Syndrome. The lawsuit claims Regenxbio made overly positive statements about the trial's success based o

Tone
Negative 14/100
Event
Regulatory and legal
Published
22 Jul 2026 00:40
Source
Pluang
Morningstar Direct company coverage

Kuehn Law Encourages Investors of Regenxbio, Inc. to Contact Law Firm

Kuehn Law, PLLC is investigating whether officers and directors of Regenxbio, Inc. (NASDAQ: RGNX) breached their fiduciary duties to shareholders. This investigation stems from a federal securities lawsuit alleging that Regenxbio provided false information regarding its RGX-111 t

Tone
Negative 28/100
Event
Regulatory and legal
Published
21 Jul 2026 23:55
Source
Morningstar
AllSci Direct company coverage

Regenxbio's Gene Therapy Shows 5-Year Vision Gains in AMD

Regenxbio reported five-year durability for its gene therapy, surabgene lomparvovec (sura-vec), showing stable to improved vision in patients with wet AMD after a single subretinal dose. These long-term results come ahead of pivotal Phase III data in Q4 2026, which will compare s

Tone
Positive 81/100
Event
Earnings
Published
20 Jul 2026 13:10
Source
AllSci
Stock Titan Direct company coverage

REGENXBIO (NASDAQ: RGNX) prices stock and warrant sale, netting $107.8M

REGENXBIO Inc. has priced an underwritten public offering of 10,003,889 shares of common stock at $9.00 per share and 1,111,111 pre-funded warrants at $8.9999 per warrant, expecting to net approximately $107.8 million after expenses, including the full exercise of the underwriter

Tone
Neutral 50/100
Event
Market update
Published
20 Jul 2026 11:34
Source
Stock Titan
The Pharma Letter Direct company coverage

Regenxbio prices expected $100M public offering

US biotech Regenxbio (Nasdaq: RGNX) announced the pricing of an underwritten public offering expected to raise around $100.0 million. The offering includes common stock at $9.00 per share and pre-funded warrants at $8.9999 per warrant. Following the announcement, the company's sh

Tone
Negative 38/100
Event
Market update
Published
20 Jul 2026 11:10
Source
The Pharma Letter
PR Newswire Direct company coverage

REGENXBIO Presents Positive Long-Term Data for Surabgene Lomparvovec in Wet AMD and Diabetic Retinopathy at American Society of Retina Specialists Annual Meeting

REGENXBIO Inc. announced positive long-term data for its investigational gene therapy, surabgene lomparvovec (sura-vec), for wet Age-related Macular Degeneration (AMD) and diabetic retinopathy (DR). The data, presented at the ASRS Annual Meeting, showed durable efficacy and safet

Tone
Positive 75/100
Event
Regulatory and legal
Published
19 Jul 2026 01:10
Source
PR Newswire
Stock Titan Direct company coverage

Five-Year Wet AMD Follow-Up Reports Stable-to-Improved Vision

REGENXBIO announced positive long-term data for its investigational gene therapy, surabgene lomparvovec (sura-vec), for wet age-related macular degeneration (wet AMD) and diabetic retinopathy (DR) at the ASRS 2026 meeting. Five-year data for wet AMD showed stable to improved visu

Tone
Positive 72/100
Event
Regulatory and legal
Published
18 Jul 2026 18:40
Source
Stock Titan
timothysykes.com Direct company coverage

REGENXBIO Stock Slides After $100M Equity Offering Pricing

REGENXBIO Inc. (RGNX) stock dropped over 11% after pricing a $100 million equity and pre-funded warrant offering at $9.00 per share. This offering, intended to fund its late-stage gene therapy pipeline, has raised concerns about dilution and near-term selling pressure. The compan

Tone
Negative 19/100
Event
Market update
Published
18 Jul 2026 14:11
Source
timothysykes.com
StocksToTrade Direct company coverage

REGENXBIO Stock Slides After $100M Equity Offering Shock

REGENXBIO Inc. (RGNX) stock dropped by 11.92% after announcing a $100 million public offering of common stock and pre-funded warrants at $9.00 per share to fund operations and pipeline development. This equity raise, coupled with a shareholder litigation firm investigating allege

Tone
Negative 19/100
Event
Market update
Published
18 Jul 2026 12:11
Source
StocksToTrade
Stock Titan Direct company coverage

REGENXBIO (NASDAQ: RGNX) launches $100M equity and pre-funded warrant raise

REGENXBIO Inc. (NASDAQ: RGNX) is conducting a primary offering of 10,003,889 shares of common stock and 1,111,111 pre-funded warrants for a total public offering price of $100 million. The public offering price is $9.00 per share and $8.9999 per warrant, with underwriters having

Tone
Negative 33/100
Event
Market update
Published
17 Jul 2026 21:09
Source
Stock Titan
GuruFocus Direct company coverage

Regenxbio (RGNX) Launches $100 Million Public Offering

Regenxbio Inc. (RGNX) announced a public offering of common stock and pre-funded warrants aimed at raising approximately $100 million to support its gene therapy research and development. The company, which has a market cap of $579.01 million, has a GF Score of 60, indicating mod

Tone
Neutral 50/100
Event
Market update
Published
17 Jul 2026 20:10
Source
GuruFocus
StocksToTrade Direct company coverage

RGNX Stock Slides As $100M Offering And Legal Heat Hit

REGENXBIO Inc. (RGNX) stock is down over 9% following news of a planned $100 million public offering of common stock and a pending investigation into its officers and directors over alleged misleading statements related to a gene therapy trial. The offering aims to fund its late-

Tone
Negative 13/100
Event
Regulatory and legal
Published
17 Jul 2026 18:09
Source
StocksToTrade
Moomoo Direct company coverage

Regenxbio Shares Fall on $100M Stock, Pre-Funded Warrant Offering

Regenxbio (RGNX) announced a public offering of $100 million in common stock and pre-funded warrants. This financial move led to a significant 10% decline in the company's shares during after-hours trading. The offering includes standard stock and warrants, which can be exercised

Tone
Negative 29/100
Event
Market update
Published
17 Jul 2026 15:10
Source
Moomoo
AllSci Direct company coverage

REGENXBIO Raises $100M for Gene Therapy Pipeline

REGENXBIO Inc. (Nasdaq: RGNX) announced a proposed underwritten public offering to raise $100 million for its gene therapy pipeline. This funding comes as the company advances multiple late-stage programs, including RGX-202 for Duchenne muscular dystrophy and RGX-121 for Hunter s

Tone
Positive 63/100
Event
Market update
Published
17 Jul 2026 15:09
Source
AllSci
timothysykes.com Direct company coverage

RGNX Stock Dips As Equity Offering And Litigation Raise Risk

REGENXBIO Inc. (RGNX) stock experienced a significant dip due to a bearish sentiment following a planned $100M public offering of common stock and ongoing shareholder litigation. The equity offering aims to fund its late-stage gene therapy pipeline but introduces dilution, while

Tone
Negative 29/100
Event
Market update
Published
17 Jul 2026 15:09
Source
timothysykes.com
PR Newswire Direct company coverage

REGENXBIO Announces Pricing of Public Offering of Common Stock and Pre-funded Warrants

REGENXBIO Inc. has announced the pricing of a public offering consisting of 10,003,889 shares of common stock at $9.00 per share and 1,111,111 pre-funded warrants at $8.9999 per warrant. The offering is expected to generate approximately $100.0 million in gross proceeds and is sl

Tone
Neutral 50/100
Event
Market update
Published
17 Jul 2026 11:09
Source
PR Newswire
Investing.com Direct company coverage

Regenxbio prices $100m public offering at $9 per share

REGENXBIO Inc. has priced an underwritten public offering of common stock and pre-funded warrants at $9 per share, aiming to raise approximately $100.0 million. This capital raise comes after a nearly 20% stock decline and a reported negative free cash flow of $236 million over t

Tone
Neutral 50/100
Event
Balance sheet
Published
17 Jul 2026 11:09
Source
Investing.com
GuruFocus Direct company coverage

REGENXBIO (RGNX) Launches $100M Public Offering at $9.00 per Sha

REGENXBIO (RGNX) announced a $100 million public offering of common shares at $9.00 each and pre-funded warrants, aiming to raise capital for its gene therapy development despite a premarket stock decline. The company has a GF Score™ of 60/100, showing moderate potential for long

Tone
Negative 29/100
Event
Market update
Published
17 Jul 2026 07:00
Source
GuruFocus
TradingView Direct company coverage

RGNX Stock Slumps 15% After-Hours — What’s Driving The Selloff?

REGENXBIO Inc. (RGNX) shares dropped 15% after-hours following the announcement of a $100 million public stock offering, sparking dilution concerns among investors. The company, which specializes in gene therapies for rare diseases, has not specified how the new funds will be uti

Tone
Negative 28/100
Event
Market update
Published
16 Jul 2026 22:42
Source
TradingView
Stock Titan Direct company coverage

REGENXBIO (NASDAQ: RGNX) targets $100M stock sale to fund gene therapy

REGENXBIO Inc. (NASDAQ: RGNX) plans a primary offering of $100 million in common stock to fund general corporate purposes, including clinical trials and pipeline development. The company anticipates receiving a $100 million milestone payment from AbbVie in July 2026 and expects i

Tone
Neutral 50/100
Event
Guidance
Published
16 Jul 2026 20:40
Source
Stock Titan
Investing.com Direct company coverage

Regenxbio plans $100 million common stock offering

REGENXBIO Inc. (NASDAQ:RGNX) announced a $100 million public offering of common stock, which will be underwritten by Morgan Stanley, J.P. Morgan, Leerink Partners, and Mizuho. The company, focused on gene therapy for rare and retinal diseases, is rapidly burning through cash, wit

Tone
Negative 40/100
Event
Balance sheet
Published
16 Jul 2026 20:40
Source
Investing.com
MSN Direct company coverage

REGENXBIO files prospectus for up to $100M common stock offering

REGENXBIO has filed a prospectus with the SEC for a common stock offering that could raise up to $100 million. The filing is a standard procedure that allows the company flexibility in future fundraising efforts. This move indicates potential plans to finance ongoing operations,

Tone
Negative 38/100
Event
Market update
Published
16 Jul 2026 20:40
Source
MSN
PR Newswire Direct company coverage

REGENXBIO Announces Proposed Public Offering of Common Stock

REGENXBIO Inc. announced its intention to offer and sell $100 million of its common stock in an underwritten public offering, contingent on market conditions. The company also plans to grant underwriters a 30-day option to purchase up to an additional 15% of the shares offered. M

Tone
Negative 36/100
Event
Market update
Published
16 Jul 2026 20:40
Source
PR Newswire
The National Law Review Direct company coverage

RGNX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Reminds Stockholders of REGENXBIO Inc. to Contact the Firm Today!

Bronstein, Gewirtz and Grossman, LLC has filed a class action lawsuit against REGENXBIO Inc. (NASDAQ: RGNX) and its officers. The lawsuit alleges that REGENXBIO made false and misleading statements regarding its gene therapy RGX‑111 for treating Hurler syndrome. Investors who pur

Tone
Negative 10/100
Event
Regulatory and legal
Published
15 Jul 2026 08:11
Source
The National Law Review